Results 41 to 50 of about 111,871 (303)

Synthetic lethality of PARP and NAMPT inhibition in triple‐negative breast cancer cells

EMBO Molecular Medicine, 2012
PARP inhibitors have been proposed as a potential targeted therapy for patients with triple‐negative (ER‐, PR‐, HER2‐negative) breast cancers. However, it is as yet unclear as to whether single agent or combination therapy using PARP inhibitors would be ...
Ilirjana Bajrami, Asha Kigozi, Antoinette Van Weverwijk, Rachel Brough, Jessica Frankum, Christopher J. Lord, Alan Ashworth   +6 more
doaj   +1 more source

PARP inhibition attenuates acute kidney allograft rejection by suppressing cell death pathways and activating PI-3K-Akt cascade. [PDF]

PLoS ONE, 2013
BACKGROUND: Novel immunosuppressive therapy facilitates long term allograft survival, but acute tubular necrosis and ischemia-reperfusion during transplantation can compromise allograft function.
Karoly Kalmar-Nagy, Peter Degrell, Aliz Szabo, Katalin Sumegi, Istvan Wittmann, Ferenc Gallyas, Balazs Sumegi   +6 more
doaj   +1 more source

Pharmacological depletion of RNA splicing factor RBM39 by indisulam synergizes with PARP inhibitors in high-grade serous ovarian carcinoma

Cell Reports, 2023
Summary: Ovarian high-grade serous carcinoma (HGSC) is the most common subtype of ovarian cancer with limited therapeutic options and a poor prognosis. In recent years, poly-ADP ribose polymerase (PARP) inhibitors have demonstrated significant clinical ...
Yuewei Xu, Sarah Spear, Yurui Ma, Marc P. Lorentzen, Michael Gruet, Flora McKinney, Yitao Xu, Chiharu Wickremesinghe, Madelen R. Shepherd, Iain McNeish, Hector C. Keun, Anke Nijhuis   +11 more
doaj   +1 more source

Niraparib in ovarian cancer. results to date and clinical potential [PDF]

, 2017
Ovarian cancer is the first cause of death from gynaecological malignancy. Germline mutation in BRCA1 and 2, two genes involved in the mechanisms of reparation of DNA damage, are showed to be related with the incidence of breast and ovarian cancer, both ...
Benedetti Panici, Pierluigi, Caruso, Davide, Papa, Anselmo, Tomao, Federica, Tomao, Silverio, Vici, Patrizia   +5 more
core   +1 more source

PARP Inhibitors for Chemoprevention—Letter [PDF]

Cancer Prevention Research, 2014
We read with great optimism To and colleagues' ([1][1]) article about PARP inhibitors as effective chemopreventive strategy for treating homologous repair (HR)–deficient tumors. Their overarching conclusion stated in the discussion is that “…synthetic lethality (i.e., PARP inhibitor ...
Saswati N, Chand, Fernando F, Blanco, Masaya, Jimbo, Theodore N, Tsangaris, Massimo, Cristofanilli, Charles J, Yeo, Jordan M, Winter, Michael J, Pishvaian, Jonathan R, Brody   +8 more
openaire   +2 more sources

CCDC6 and USP7 expression levels suggest novel treatment options in high-grade urothelial bladder cancer

Journal of Experimental & Clinical Cancer Research, 2019
Background The muscle invasive form of urothelial bladder cancer (UBC) is a deadly disease. Currently, the therapeutic approach of UBC is mostly based on surgery and standard chemotherapy.
Francesco Morra, Francesco Merolla, Daniela Criscuolo, Luigi Insabato, Riccardo Giannella, Gennaro Ilardi, Aniello Cerrato, Roberta Visconti, Stefania Staibano, Angela Celetti   +9 more
doaj   +1 more source

The kinesin Eg5 inhibitor K858 induces apoptosis but also survivin-related chemoresistance in breast cancer cells [PDF]

, 2016
Inhibitors of kinesin spindle protein Eg5 are characterized by pronounced antitumor activity. Our group has recently synthesized and screened a library of 1,3,4-thiadiazoline analogues with the pharmacophoric structure of K858, an Eg5 inhibitor.
CARRADORI, Simone, DE IULIIS, FRANCESCA, giantulli, sabrina, GIUFFRIDA, Anna, MILANA, Bernardina, SALERNO, GERARDO, SCARPA, Susanna, SILVESTRI, Ida, Taglieri, Ludovica   +8 more
core   +1 more source

Inhibiting stearoyl‐CoA desaturase suppresses bone metastatic prostate cancer by modulating cellular stress, mTOR signaling, and DNA damage response

FEBS Letters, EarlyView.
Bone metastasis in prostate cancer (PCa) patients is a clinical hurdle due to the poor understanding of the supportive bone microenvironment. Here, we identify stearoyl‐CoA desaturase (SCD) as a tumor‐promoting enzyme and potential therapeutic target in bone metastatic PCa.
Alexis Wilson, Mackenzie K Herroon, Shane Mecca, Laimar C Garmo, Jacob Lindquist, Shrila Rajendran, Steve M. Patrick, Izabela Podgorski   +7 more
wiley   +1 more source

SOX5 inhibition overcomes PARP inhibitor resistance in BRCA-mutated breast and ovarian cancer

Cell Death and Disease
Poly (ADP-ribose) polymerase (PARP) inhibitors are effective in cells with homologous recombination (HR) deficiency, including BRCA1/2 mutation. However, PARP inhibitors remain a therapeutic challenge in breast and ovarian cancer due to inevitably ...
Mithun Ghosh, Min Sil Kang, Nar Bahadur Katuwal, Sa Deok Hong, Seong Min Park, Seul-Gi Kim, Seung Ryeol Lee, Yong Wha Moon   +7 more
doaj   +1 more source

Efficacy of a platinum-based chemotherapy rechallenge for platinum-sensitive recurrence after PARP inhibitor maintenance

Gynecologic Oncology Reports
Objective: Platinum-free interval (PFI) is the period from the end of platinum-based chemotherapy to the date of recurrence. If the PFI is > 6 months, a platinum-based chemotherapy rechallenge is considered; however, its efficacy after poly adenosine 5 ...
Takehiro Nakao, Kenichi Harano, Masashi Wakabayashi, Yoichi Naito, Hiroshi Tanabe, Toru Mukohara   +5 more
doaj   +1 more source